A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias

• Egile Nagusiak: Oksana Montecchini (Egilea), Stefania Braidotti (Egilea), Raffaella Franca (Egilea), Giulia Zudeh (Egilea), Christian Boni (Egilea), Claudio Sorio (Egilea), Eleonora Toffoletti (Egilea), Marco Rabusin (Egilea), Alberto Tommasini (Egilea), Giuliana Decorti (Egilea), Gabriele Stocco (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The pathogenic role of the overactivated ABL1 tyrosine kinase (TK) pathway is well recognized in some forms of BCR-ABL1 like acute lymphoblastic leukemia (ALL); TK inhibitors represent a useful therapeutic choice in these patients who respond poorly to conventional chemotherapy. Here we report a nov...